Edition:
United States

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

75.60CHF
15 Jun 2018
Change (% chg)

CHF0.10 (+0.13%)
Prev Close
CHF75.50
Open
CHF75.82
Day's High
CHF76.14
Day's Low
CHF75.60
Volume
13,747,991
Avg. Vol
5,308,432
52-wk High
CHF88.30
52-wk Low
CHF72.68

Latest Key Developments (Source: Significant Developments)

Rovi Signs Distribution Agreement With Sandoz
Tuesday, 12 Jun 2018 06:07am EDT 

June 12 (Reuters) - Rovi ::REACHES AGREEMENT WITH SANDOZ, A UNIT OF NOVARTIS, FOR DISTRIBUTION AND MARKETING OF ITS ENOXAPARIN BIOSIMILAR.GRANTS SANDOZ AN EXCLUSIVE LICENSE TO MARKET PRODUCT IN HONG KONG, SINGAPORE AND VIETNAM.  Full Article

Regenxbio Receives $100 Mln Accelerated License Payment
Monday, 11 Jun 2018 04:05pm EDT 

June 11 (Reuters) - Regenxbio Inc ::REGENXBIO RECEIVES $100 MILLION ACCELERATED LICENSE PAYMENT DUE TO ACQUISITION OF AVEXIS BY NOVARTIS.REGENXBIO - ACCELERATED LICENSE PAYMENT CONSISTED OF $60 MILLION IN ANNUAL FEES AND A COMMERCIAL MILESTONE FEE OF $40 MILLION.REGENXBIO INC - NOVARTIS NOW HOLDS EXCLUSIVE RIGHTS TO NAV TECHNOLOGY PLATFORM FOR DEVELOPMENT OF TREATMENTS FOR SMA.REGENXBIO INC - REGENXBIO REMAINS ELIGIBLE TO RECEIVE A POTENTIAL COMMERCIAL MILESTONE FEE.  Full Article

Novartis Completes Sale Of Stake In Consumer Healthcare JV To GSK
Friday, 1 Jun 2018 08:00am EDT 

June 1 (Reuters) - NOVARTIS AG ::COMPLETES SALE OF STAKE IN CONSUMER HEALTHCARE JOINT VENTURE TO GSK FOR USD13.0 BILLION.  Full Article

Novartis, Amgen Announce FDA Approval Of Aimovig Treatment For Migraine Prevention
Thursday, 17 May 2018 07:11pm EDT 

May 17 (Reuters) - Novartis Ag ::NOVARTIS AND AMGEN ANNOUNCE FDA APPROVAL OF AIMOVIG™ (ERENUMAB-AOOE), A NOVEL TREATMENT DEVELOPED SPECIFICALLY FOR MIGRAINE PREVENTION.EMA MARKETING AUTHORIZATION APPLICATION FOR AIMOVIG IS UNDER REVIEW. NOVARTIS EXPECTS APPROVAL IN EU IN COMING MONTHS.  Full Article

Novartis says set to deliver sales growth, margin expansion through 2022
Wednesday, 16 May 2018 01:21am EDT 

May 16 (Reuters) - Novartis AG ::SAYS POSITIONED TO DELIVER SALES GROWTH AND MARGIN EXPANSION THROUGH 2022.SAYS ALCON RETURNING TO A POSITION OF STRENGTH AS WORLD'S LEADING EYE CARE DEVICES COMPANY.CEO SAYS FIRM MADE MISTAKES RECENTLY AND WORLD RIGHTLY EXPECTS MORE FROM A LEADING HEALTHCARE COMPANY.SAYS DESPITE CONTINUING US PRICING PRESSURE, GLOBALLY, SANDOZ GROSS MARGIN IS IMPROVING.SAYS IN US, SANDOZ IS OPTIMIZING PORTFOLIO THROUGH TARGETED PRUNING AND LEARNING FROM RECENT SETBACKS.SAYS MANAGEMENT HIGHLIGHTS ACTIONS THAT HAVE RETURNED BUSINESS TO GROWTH AND IMPROVED MARGINS.SAYS ALCON STRATEGIC REVIEW IS ON TRACK WITH ACTION NOT EXPECTED BEFORE FIRST HALF OF 2019.SAYS ALCON EXPECTS TO RETURN TO LONG-TERM, SUSTAINABLE GROWTH WITH MARGINS IN LINE WITH INDUSTRY PEERS.  Full Article

Novartis Successfully Completes Acquisition Of Avexis
Tuesday, 15 May 2018 04:00pm EDT 

May 15 (Reuters) - Novartis AG ::NOVARTIS SUCCESSFULLY COMPLETES ACQUISITION OF AVEXIS, INC..  Full Article

Novartis AG says Cohen contract not linked to CEO dinner with Trump
Wednesday, 9 May 2018 11:43am EDT 

May 9 (Reuters) - Novartis AG ::SAYS HIRED ESSENTIAL CONSULTANTS BECAUSE BELIEVED MICHAEL COHEN COULD ADVISE ON HOW TRUMP ADMINISTRATION MIGHT APPROACH U.S. HEALTHCARE POLICY, INCLUDING AFFORDABLE CARE ACT.SAYS THE AGREEMENT WAS FOR A TERM OF ONE YEAR, AND PAID ESSENTIAL CONSULTANTS 100,000 USD PER MONTH.SAYS NOVARTIS HAD FIRST MEETING WITH MICHAEL COHEN IN MARCH 2017, SAYS DETERMINED AFTER MEETING THAT COHEN WOULD BE UNABLE TO PROVIDE THE SERVICES ANTICIPATED.SAYS COHEN CONTRACT COULD ONLY BE TERMINATED FOR CAUSE, SO PAYMENTS CONTINUED TO BE MADE UNTIL THE CONTRACT EXPIRED BY ITS OWN TERMS IN FEBRUARY 2018.SAYS CONTRACT WAS IN NO WAY RELATED TO GROUP DINNER CEO NARASIMHAN ATTENDED AT THE WORLD ECONOMIC FORUM IN DAVOS WITH PRESIDENT TRUMP.  Full Article

Novartis Launches Focalview App
Wednesday, 25 Apr 2018 01:15am EDT 

April 25 (Reuters) - Novartis AG ::NOVARTIS LAUNCHES FOCALVIEW APP, PROVIDING OPPORTUNITY FOR PATIENTS TO PARTICIPATE IN OPHTHALMOLOGY CLINICAL TRIALS FROM HOME.  Full Article

Novartis AG Says Appoints John Tsai Head Of Global Drug Development And Chief Medical Officer
Thursday, 19 Apr 2018 01:18am EDT 

April 19 (Reuters) - Novartis AG ::SAYS APPOINTS JOHN TSAI HEAD OF GLOBAL DRUG DEVELOPMENT AND CHIEF MEDICAL OFFICER.  Full Article

Novartis Drug Afinitor Disperz Receives FDA Approval To Treat TSC-Associated Partial Onset Seizures
Tuesday, 10 Apr 2018 07:51pm EDT 

April 10 (Reuters) - Novartis AG ::NOVARTIS DRUG AFINITOR DISPERZ® RECEIVES FDA APPROVAL TO TREAT TSC-ASSOCIATED PARTIAL - ONSET SEIZURES.AFINITOR DISPERZ RECEIVES FDA APPROVAL TO TREAT TSC-ASSOCIATED PARTIAL-ONSET SEIZURES.  Full Article

BRIEF-FDA Allows Label For Novartis' Drug Cosentyx To Include Psoriatic Arthritis Benefit

* NOVARTIS RECEIVES FDA APPROVAL FOR INCLUSION OF NEW EVIDENCE THAT COSENTYX® INHIBITS PROGRESSION OF JOINT STRUCTURAL DAMAGE IN PSORIATIC ARTHRITIS